
Bambusa Therapeutics, Inc.
BBTXFiledBambusa Therapeutics, Inc. · Nasdaq Global Select Market · latest filing 2026-10-09
Preliminary IPO registration remains incomplete, with core pricing and share-count terms blank.
As of the October 9, 2026 S-1 filing, Bambusa had applied for Nasdaq listing, but the preliminary prospectus left pricing, offering size, and delivery date blank.
Capital destination
Awaiting verificationS-1 · 2026-10-09
Share-type percentages are not net-proceeds percentages. Amounts retain their stated gross/net basis; do not add unlike bases.
Check the source · S-1 ↗Capital destination
Awaiting verificationS-1 · 2026-10-09
Share-type percentages are not net-proceeds percentages. Amounts retain their stated gross/net basis; do not add unlike bases.
Check the source · S-1 ↗Names not yet published
Fully diluted valuation bridge
| Status | Reference |
|---|---|
| Awaiting verification | Source ↗ |
Basic-price scenario
A verified single offer price and basic post-offer share count are required. This is a data gap, not a paid lock.
Check the source · S-1 ↗Holder data awaits verification
Pre-offering beneficial ownership is disclosed using a 25,740,828-share denominator, but after-offering share counts and percentages are blank in the supplied table. Voting and investment powers vary by holder. · 2026-10-09
Pre-offering beneficial ownership is disclosed using a 25,740,828-share denominator, but after-offering share counts and percentages are blank in the supplied table. Voting and investment powers vary by holder.
One disclosed holder; not a complete ownership distribution.Check the source · S-1 ↗Conditional lock-up timeline
| Status | Reference |
|---|---|
| Awaiting verification | Source ↗ |
Financial quality and runway
| Status | Reference |
|---|---|
| Awaiting verification | Source ↗ |
Latest filing update
Loading saved filing update…
SEC filing history
Loading filing history…
The company depends entirely on product-candidate success and has no approved products or product revenue.
- Potential impact
- Awaiting verification
- Monitor
- A future amended or effective prospectus may disclose pricing, size, final underwriting terms, and a verified closing; no date is supplied.
- Evidence
- Risk Factors Summary ↗